secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000875320-24-000137
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q1 product revenue $2.69B (+13% YoY); reiterates FY guidance; $4.9B Alpine acquisition
--------------------------------------------------------------------------------

- Q1 product revenue $2.69B, up 13% YoY; GAAP net income up 57%; Non-GAAP net income up 56%.
- Reiterates FY2024 product revenue guidance $10.55-$10.75B; combined non-GAAP R&D and SG&A $4.3-$4.4B.
- Submitted NDA (priority review) for vanzacaftor triple in CF to FDA and MAA to EMA; rolling NDA for suzetrigine in acute pain.
- Entered agreement to acquire Alpine Immune Sciences for ~$4.9B ($65/sh cash); expected close Q2 2024.
- Cash and marketable securities $14.6B; >25 CASGEVY ATCs activated globally; multiple patients started cell collection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000137/0000875320-24-000137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000137/vrtx-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000875320-24-000137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer